The first and only subcutaneous therapy that achieves dual-targeted inhibition of EGFR and MET^1,2

Select a tumor type:

EGFR+ Metastatic
Non–Small Cell Lung Cancer¹

Exon 19 deletion/Exon 21 L858R substitution mutations
Exon 20 insertion mutations

LEARN MORE

NOW APPROVED

R/M Head and Neck Squamous Cell Carcinoma¹

For adults who progressed on or after platinum-based chemotherapy and an anti–PD-(L)1 antibody

LEARN MORE

Not indicated for patients with OPSCC that is HPV-associated (ie, by p16 IHC).¹
This indication is approved under accelerated approval. Continued approval for this indication may be contingent on confirmatory trial(s).¹

EGFR, epidermal growth factor receptor; HPV, human papillomavirus; IHC, immunohistochemistry; MET, mesenchymal-epithelial transition; OPSCC, oropharyngeal squamous cell carcinoma; PD-(L)1, programmed cell death (ligand) protein 1; R/M, recurrent or metastatic.

References: 1. RYBREVANT FASPRO [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. National Cancer Institute. Drugs approved for head and neck cancer. Updated May 8, 2025. Accessed September 1, 2026. https://www.cancer.gov/about-cancer/treatment/drugs/head-neck

The first and only subcutaneous therapy that achieves dual-targeted inhibition of EGFR and MET1,2

EGFR+ Metastatic Non–Small Cell Lung Cancer1

R/M Head and Neck Squamous Cell Carcinoma1

The first and only subcutaneous therapy that achieves dual-targeted inhibition of EGFR and MET^1,2

EGFR+ Metastatic
Non–Small Cell Lung Cancer¹

R/M Head and Neck Squamous Cell Carcinoma¹